{"timeline":{"headline":"Diabetic Retinopathy Study (DRS)","type":"default","text":"History of NCT00000160","startDate":"2005,06,23","date": [{"startDate":"2005,06,23","headline":"View of NCT00000160 on 2005_06_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Xenon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Argon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 79144261</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 81261561</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 81271665</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 85100334</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 85233792</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 76181969</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 88014959</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 87212748</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 89108733</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.htm</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,06,30","headline":"View of NCT00000160 on 2005_06_30","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_30</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Xenon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Argon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 79144261</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 81261561</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 81271665</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 85100334</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 85233792</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 76181969</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 88014959</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 87212748</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 89108733</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.htm</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000160&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_06_</span><del style=\"background:#ffe6e6;\">2</del><span>3</span><ins style=\"background:#e6ffe6;\">0</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Diabetic Retinopathy Study (DRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.&lt;br/&gt;<br/>&lt;br/&gt; One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.&lt;br/&gt;<br/>&lt;br/&gt;Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Diabetic Retinopathy<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Blindness<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Xenon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Argon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 79144261&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81261561&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81271665&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85100334&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85233792&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 76181969&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 88014959&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 87212748&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 89108733&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.htm&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1972-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;70 Years&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-62&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,12,08","headline":"View of NCT00000160 on 2005_12_08","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_12_08</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Xenon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Argon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 79144261</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 81261561</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 81271665</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 85100334</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 85233792</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 76181969</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 88014959</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 87212748</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 89108733</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.htm</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000160&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_</span><del style=\"background:#ffe6e6;\">06_30</del><ins style=\"background:#e6ffe6;\">12_08</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Diabetic Retinopathy Study (DRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.&lt;br/&gt;<br/>&lt;br/&gt; One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.&lt;br/&gt;<br/>&lt;br/&gt;Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Diabetic Retinopathy<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Blindness<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Xenon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Argon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 79144261&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81261561&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81271665&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85100334&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85233792&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 76181969&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 88014959&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 87212748&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 89108733&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.htm&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1972-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;70 Years&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-62&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2006,04,26","headline":"View of NCT00000160 on 2006_04_26","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2006_04_26</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Xenon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Argon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 79144261</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 81261561</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 81271665</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 85100334</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 85233792</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 76181969</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 88014959</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 87212748</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 89108733</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000160&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;200</span><del style=\"background:#ffe6e6;\">5_12_08</del><ins style=\"background:#e6ffe6;\">6_04_26</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Diabetic Retinopathy Study (DRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.&lt;br/&gt;<br/>&lt;br/&gt; One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.&lt;br/&gt;<br/>&lt;br/&gt;Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Diabetic Retinopathy<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Blindness<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Xenon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Argon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 79144261&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81261561&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81271665&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85100334&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85233792&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 76181969&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 88014959&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 87212748&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 89108733&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.</span><del style=\"background:#ffe6e6;\">htm</del><ins style=\"background:#e6ffe6;\">asp</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/news/pressreleases/drspressrelease.htm&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1972-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;70 Years&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-62&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2006,06,01","headline":"View of NCT00000160 on 2006_06_01","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2006_06_01</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Xenon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Argon Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 79144261</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 81261561</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 81271665</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 85100334</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 85233792</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 76181969</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 88014959</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 87212748</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 89108733</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.asp</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000160&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2006_0</span><del style=\"background:#ffe6e6;\">4_26</del><ins style=\"background:#e6ffe6;\">6_01</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Diabetic Retinopathy Study (DRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.&lt;br/&gt;<br/>&lt;br/&gt; One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.&lt;br/&gt;<br/>&lt;br/&gt;Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Diabetic Retinopathy<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Blindness<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Xenon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Argon Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 79144261&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81261561&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 81271665&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85100334&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 85233792&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 76181969&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 88014959&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 87212748&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 89108733&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/news/pressreleases/drspressrelease.</span><del style=\"background:#ffe6e6;\">htm</del><ins style=\"background:#e6ffe6;\">asp</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1972-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;70 Years&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-62&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2014,03,14","headline":"View of NCT00000160 on 2014_03_14","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000160</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2014_03_14</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Diabetic Retinopathy Study (DRS)</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.<br/>\n<br/> One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.<br/>\n<br/>Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Diabetic Retinopathy\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Blindness\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Xenon Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Argon Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226</div>\n<div>MEDLINE: 7195893</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655</div>\n<div>MEDLINE: 426679</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261</div>\n<div>MEDLINE: 7262408</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600</div>\n<div>MEDLINE: 7196564</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381</div>\n<div>MEDLINE: 6394209</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991</div>\n<div>MEDLINE: 2409053</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396</div>\n<div>MEDLINE: 944535</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760</div>\n<div>MEDLINE: 3658347</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809</div>\n<div>MEDLINE: 3555429</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28</div>\n<div>MEDLINE: 2912911</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp</td>\n</tr>\n<tr>\n<th>URL</th><td>http://www.nei.nih.gov/news/pressreleases/drspressrelease.asp</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)</p>\n</td>\n</tr>\n<tr>\n<th>See also</th><td>\n<p>NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Completed</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1972-01\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Maximum age</th><td>70 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-62</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000160&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;20</span><del style=\"background:#ffe6e6;\">06_06_01</del><ins style=\"background:#e6ffe6;\">14_03_14</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Diabetic Retinopathy Study (DRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether photocoagulation helps prevent severe visual loss from proliferative diabetic retinopathy.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether a difference exists in the efficacy and safety of argon versus xenon photocoagulation for proliferative diabetic retinopathy.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;By the 1950s, diabetic retinopathy had become a leading cause of blindness and visual disability in the United States. \u00a0The use of photocoagulation to treat proliferative retinopathy gained widespread use in ophthalmic practice following its introduction in 1959. However, only a few studies of photocoagulation incorporated any of the basic principles of controlled clinical trials, and these involved inadequate numbers of patients. \u00a0Consequently, there has been inadequate evidence of the actual value of the procedure. Because of the clinical importance of diabetic retinopathy and the increasing use of photocoagulation in its management, the Diabetic Retinopathy Study (DRS) was begun in 1971. \u00a0This randomized, controlled clinical trial involved more than 1,700 patients enrolled at 15 medical centers.&lt;br/&gt;<br/>&lt;br/&gt; One eye of each patient was randomly assigned to immediate photocoagulation and the other to followup without treatment, regardless of the course followed by either eye. \u00a0The eye chosen for photocoagulation was randomly assigned to either of two treatment techniques, one using an argon laser and the other a xenon arc photocoagulator. \u00a0Patients were followed at 4-month intervals according to a protocol that provided for measurement of best corrected visual acuity.&lt;br/&gt;<br/>&lt;br/&gt;Treatment was usually completed in one or two sittings and included scatter (panretinal) photocoagulation extending to or beyond the vortex vein ampulae. \u00a0The argon treatment technique specified 800 to 1,600, 500-micron scatter burns of 0.1 second duration and direct treatment of new vessels whether on or within one disc diameter of the optic disc (NVD) or outside this area (NVE). \u00a0Focal treatment was also applied to microaneurysms or other lesions thought to be causing macular edema. \u00a0Followup treatment was applied as needed at 4-month intervals. \u00a0The xenon technique was similar, but scatter burns were fewer in number, generally of longer duration, and stronger, and direct treatment was applied only to NVE on the surface of the retina.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Diabetic Retinopathy<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Blindness<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Xenon Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Argon Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; A modification of the Airlie House classification of diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 7., Invest Ophthalmol Vis Sci 1981;21/part 2:149-209&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Design, methods, and baseline results.  Diabetic Retinopathy Study (DRS) Report Number 6., Invest Ophthalmol Vis Sci 1981;2:210-226&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 7195893&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study., Arch Ophthalmol 1979;97:654-655&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">79144261</del><ins style=\"background:#e6ffe6;\">426679</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: A short report of long range results., Diabetic Retinopathy Study (DRS) Report Number 4. Proceedings of the 10th Congress of the International Diabetes Federation 1979&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Relationship of adverse treatment effects to retinopathy severity.  Diabetic Retinopathy Study (DRS) Report Number 5., Dev Ophthalmol 1981;2:248-261&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">81261561</del><ins style=\"background:#e6ffe6;\">7262408</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings.  Diabetic Retinopathy Study (DRS) Report Number 8., Ophthalmol 1981;88:583-600&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">81271665</del><ins style=\"background:#e6ffe6;\">7196564</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ederer F; Podgor MJ; The Diabetic Retinopathy Study Research Group; Assessing possible late treatment effects in stopping a clinical trial early: A case study.  Diabetic Retinopathy Study (DRS) Report Number 9., Controlled Clinical Trials 1984;5:373-381&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">85100334</del><ins style=\"background:#e6ffe6;\">6394209</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Rand LI; Prud'homme GJ; Ederer F; Canner PL; The Diabetic Retinopathy Study Research Group; Factors influencing the development of visual loss in advanced diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 10., Invest Ophthalmol Vis Sci 1985;26:983-991&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">85233792</del><ins style=\"background:#e6ffe6;\">2409053</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Preliminary report on the effect of photocoagulation therapy., Am J Ophthalmol 1976;81:383-396&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">76181969</del><ins style=\"background:#e6ffe6;\">944535</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Ferris FL; Podgor MJ; Davis MD; The Diabetic Retinopathy Study Research Group; Macular edema in Diabetic Retinopathy Study Patients.  Diabetic Retinopathy Study (DRS) Report Number 12., Ophthalmol 1987;94:754-760&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">88014959</del><ins style=\"background:#e6ffe6;\">3658347</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Swartz M; The Diabetic Retinopathy Study Research Group; Intraocular pressure following panretinal photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 11., Arch Ophthalmol 1987;97:807-809&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">87212748</del><ins style=\"background:#e6ffe6;\">3555429</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Kaufman SC; Ferris FL; Siegel DG; Davis MD; The Diabetic Retinopathy Study Research Group; Factors associated with visual outcome after photocoagulation for diabetic retinopathy.  Diabetic Retinopathy Study (DRS) Report Number 13., Invest Ophthalmol Vis Sci 1989;30:23-28&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">8</del><ins style=\"background:#e6ffe6;\">2</ins><span>91</span><del style=\"background:#ffe6e6;\">08733</del><ins style=\"background:#e6ffe6;\">2911</ins><span>&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14., Invest Ophthalmol Clin 1994;27:239-253&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: The Diabetic Retinopathy Study Research Group; Photocoagulation treatment of proliferative diabetic reinopathy: The second report from the Diabetic Retinopathy Study, Arch Ophthalmol 1978;85:81-106&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/NEWS/clinicalalerts/alert-etdrs.asp&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;URL&lt;/th&gt;&lt;td&gt;http://www.nei.nih.gov/news/pressreleases/drspressrelease.asp&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Clinical Alert to Ophthalmologists\u2014Early Treatment Diabetic Retinopathy Study (ETDRS)&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;See also&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;NEI Press Release-Laser Treatment Effective for Diabetic Retinopathy&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;</span><del style=\"background:#ffe6e6;\"><br/>            Completed<br/> </del><ins style=\"background:#e6ffe6;\">Completed</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1972-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients were eligible if they had best corrected visual acuity of 20/100 or better in each eye and the presence of proliferative diabetic retinopathy in at least one eye or severe nonproliferative retinopathy in both eyes. \u00a0They could not have had prior treatment with photocoagulation or pituitary ablation, and both eyes had to be suitable for photocoagulation. \u00a0All eligible patients were younger than 70 years, and the examining physician assessed the outlook for survival and availability for 5 years of followup to be good.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/> </span><del style=\"background:#ffe6e6;\">&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A</del><span></span><ins style=\"background:#e6ffe6;\"></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;70 Years&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-62&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}